Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02747641
Other study ID # FLA 15-110
Secondary ID
Status Completed
Phase N/A
First received April 12, 2016
Last updated November 17, 2017
Start date May 2016
Est. completion date August 2017

Study information

Verified date October 2016
Source Alma Lasers Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects. The primary endpoint is to assess the change in the vaginal dryness by means of a Visual Analogic Scale (10 cm VAS) and/or Bachmann Index in VVA. The clinical improvement will be assessed by patient filled Vulvovaginal Atrophy.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date August 2017
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years to 70 Years
Eligibility Inclusion Criteria:

- Healthy, non-smoking

- Woman, age 35 to 70 yrs, menopausal

- Provided written Informed Consent

- Exhibiting VVA and/or SUI symptoms (mild or moderate SUI, according to severity index developed by Sandvik.)

- Prolapse staged < II, according to the pelvic organ prolapse quantification (ICS-POP-Q) system

- Normal PAP smear (up to 1 year prior to baseline)

- Vaginal canal, introitus and vestibule free of injuries and bleeding

- Have not had procedures in the anatomical area through 6 months prior to treatment

- Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits

Exclusion Criteria:

- Severe prolapse (POP>= grade 3)

- Use of photosensitive drugs

- Acute or recurrent urinary tract infection (UTI), or genital infection (e.g. herpes candida).

- Any serious disease, or chronic condition, that could interfere with the study compliance

- Acute or actively present within the last 2 months HPV/HSV

- Undiagnosed vaginal bleeding

- Urge or overflow incontinence

- Patients who are on antidepressants, or a-adrenergic and anticholinergic medications

- Patients with immune system diseases.

- Patients with allergic reaction to laser.

- Obese women (BMI >30)

- Patient unable to follow post-treatment instructions

- History of keloid formation

- Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E or anti inflammatories within 2 weeks pre treatment

- A history of thrombophlebitis

- A history of acute infections

- A history of heart failure

- Previously undergone reconstructive pelvic surgery

- Have used vaginal creams, moisturizers, lubricants or homeopathic preparations for at least 3 months

- Any medical condition that in the investigators opinion would interfere with the patients participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pixel CO2 Laser System


Locations

Country Name City State
United States The Cleveland Clinic Weston Florida

Sponsors (2)

Lead Sponsor Collaborator
Alma Lasers Inc. The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vulvovaginal Atrophy (VVA) Utilizing Bachman Vaginal Health Index 6 months
See also
  Status Clinical Trial Phase
Completed NCT06136975 - Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
Recruiting NCT04081805 - LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2) N/A
Completed NCT04039555 - Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER) N/A
Active, not recruiting NCT02704741 - Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments N/A
Completed NCT01975129 - A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin Phase 2
Completed NCT04735549 - Vulvovaginal Atrophy Correction Using Neodymium Laser N/A
Completed NCT04079218 - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Phase 4
Completed NCT03063684 - Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus N/A
Recruiting NCT05953090 - VALOR: Vaginal Atrophy & Long-term Observation of Recovery N/A
Not yet recruiting NCT05483634 - Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause
Completed NCT04717245 - Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment N/A
Completed NCT02937805 - Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes N/A
Completed NCT02967510 - Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy Phase 2
Not yet recruiting NCT02571127 - Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness. Phase 4
Completed NCT00238732 - Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause Phase 3
Completed NCT02413008 - A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting Phase 2
Completed NCT03493126 - Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function Phase 4
Not yet recruiting NCT03238053 - Laser Treatment of Genito-urinary Syndrome in Women N/A
Terminated NCT01753102 - Efficacy and Safety Of Spil's Estradiol Vaginal Tablet Phase 3
Terminated NCT05627791 - Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman Phase 2/Phase 3